ADMET-AI
Predict 41 TDC ADMET endpoints and 8 RDKit descriptors from SMILES with Chemprop-RDKit graph neural networks — hERG, AMES, DILI, CYP450 and clearance.
ADMET-AI predicts absorption, distribution, metabolism, excretion, and toxicity liabilities across a broad panel of endpoints straight from SMILES. Reach for it for a fast, broad first screen — early hit triage and library-scale prioritization — when you want to flag safety and pharmacokinetic risks before committing synthesis. ADMETLab3, which offered a wider endpoint set, is no longer available, so ADMET-AI is the platform's ADMET predictor. See what you can achieve for the full set.
How ADMET-AI results compare to the bench
What an ADMET-AI probability has been shown to agree with, why the comparison is one step removed from an assay, and which endpoints do not translate.
Try it
ADMET-AI integration in .bloom* platform
ADMET-AI is a state-of-the-art machine learning platform for fast and accurate ADMET property prediction. Developed by researchers at Stanford University, it uses Chemprop-RDKit graph neural networks trained on 41 ADMET datasets from the Therapeutics Data Commons (TDC). Through .bloom*'s webapp, you can screen compound libraries for pharmacokinetic and safety properties without complex setup.
Citations
Swanson K, Walther P, Leitz J, Mukherjee S, Wu JC, Shivnaraine RV, Zou J. ADMET-AI: a machine learning ADMET platform for evaluation of large-scale chemical libraries. Bioinformatics. 2024 Jul 1;40(7):btae416. doi: 10.1093/bioinformatics/btae416
Huang K, Fu T, Gao W, Zhao Y, Roohani Y, Leskovec J, Coley CW, Xiao C, Sun J, Zitnik M. Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development. NeurIPS Datasets and Benchmarks. 2021. arXiv: 2102.09548 · https://tdcommons.ai
Technical foundation
Model architecture
ADMET-AI uses Chemprop-RDKit, a graph neural network architecture that combines:
- Message passing neural networks for molecular graph representation
- RDKit-computed molecular descriptors as additional features
- Trained on the Therapeutics Data Commons (TDC) ADMET Benchmark datasets
Performance benchmarks
Every figure below is author-reported, carries the dataset and sample size it was measured on, and comes from TDC's scaffold-split test sets — the setting where the model must generalise to chemical series it did not train on. Read how ADMET-AI results compare to the bench before acting on any of them.
- Toxicity classifiers: hERG AUROC 0.840 (hERG, n = 655) · mutagenicity 0.850 (AMES, n = 7278) · drug-induced liver injury 0.887 (DILI, n = 475).
- Strongest regression endpoints: aqueous solubility MAE 0.761 log mol/L (AqSolDB, n = 9982) and lipophilicity MAE 0.467 log-ratio (AstraZeneca, n = 4200) — best on the leaderboard for both.
- Weakest endpoints, and they are the pharmacokinetic ones: half-life Spearman 0.239 (Obach, n = 667) and volume of distribution Spearman 0.389 (Lombardo, n = 1130). Do not read these as quantities.
- Highest average rank across the 22 TDC ADMET Benchmark Group datasets as of the paper's snapshot (4 October 2023). That is an average: on the same snapshot the model ranked 10th on volume of distribution and 11th on blood–brain barrier.
- Fastest of the public ADMET web servers measured in the 2024 paper — a 45% time reduction over the next fastest for 1000 molecules. That comparison is on speed only, not accuracy.
Webapp input and processing capabilities
Compound input methods
Direct SMILES entry:
- Paste individual SMILES strings with instant validation
- Real-time structure preview and property calculation
- Support for stereochemistry and complex molecules
Batch file processing:
- Upload CSV files with SMILES in the first column
- Support for multi-molecule SDF files
- Automatic format detection and parsing
- Progress tracking for large datasets (thousands of compounds)
Integration with other tools:
- Direct import from generative chemistry tools (DeepPurpose, AiZynthFinder)
- Connection to virtual screening results
- Import from compound library searches (ZINC, PubChem)
Prediction endpoints available
ADMET-AI computes 8 physicochemical properties using RDKit and predicts 41 ADMET properties across the following categories:
Absorption predictions:
- Caco-2 permeability: Intestinal absorption prediction
- HIA: Human intestinal absorption classification
- Pgp inhibition/substrate: P-glycoprotein interaction predictions
- Bioavailability: Oral bioavailability classification
Distribution predictions:
- BBB permeability: Blood-brain barrier penetration
- PPB: Plasma protein binding (fraction unbound)
- VDss: Volume of distribution at steady state
Metabolism predictions:
- CYP450 inhibition: CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4 inhibition
- CYP450 substrate: Substrate classification for CYP2C9, CYP2D6, CYP3A4
Excretion predictions:
- Clearance: hepatocyte and microsomal clearance, as regression values in the assay's own units. There is no renal clearance model
- Half-life: a regression value in hours, not a stability class — and the weakest endpoint the model reports
Toxicity predictions:
- hERG inhibition: cardiotoxicity risk (QT prolongation)
- AMES toxicity: mutagenicity prediction
- DILI: drug-induced liver injury risk
- Skin reaction: dermal toxicity potential (n = 404)
- Carcinogenicity: carcinogen classification (n = 278)
- Clinical trial toxicity and acute toxicity (LD50): two separate endpoints — a binary ClinTox probability and an LD50 regression value
- Tox21 panel: 12 nuclear-receptor and stress-response assay endpoints. These are a toxicity screen, not an off-target selectivity panel
Quality control and validation
Structure processing:
- Automatic SMILES canonicalization and standardization
- Salt stripping and neutralization
- Duplicate detection and removal
- Structure validation with detailed error reporting
Prediction reliability:
- Confidence scores for each prediction
- Applicability domain assessment based on training set similarity
- Model version tracking for reproducibility
- Uncertainty quantification via 5-model ensemble predictions
No reliability field tells you whether the model has seen chemistry resembling your molecule. That is the dominant caveat on every number here, and it is unmeasured — see translatability.
When to use ADMET-AI in drug discovery
Early compound evaluation
Virtual screening triage:
- Filter large compound libraries before synthesis
- Prioritize compounds with favorable ADMET profiles
- Flag molecules with potential safety concerns
- Order the wet-lab queue — not replace it. No endpoint here is validated to substitute for its assay
Lead optimization:
- Assess ADMET properties of hit compounds
- Guide medicinal chemistry optimization decisions
- Balance potency with developability parameters
- Identify compounds requiring formulation development
Compound library design:
- Evaluate virtual compound collections
- Design libraries with improved ADMET properties
- Assess synthetic accessibility alongside drug-like properties
- Optimize for multiple parameter objectives
Safety triage
These are internal triage uses. ADMET-AI is not qualified under ICH M7 or any other guideline that admits a computed prediction in place of a test, so nothing here is suitable for a regulatory submission.
Safety profiling:
- Early flagging of toxicological liabilities
- A cardiotoxicity signal (hERG probability) to prioritize a patch-clamp assay
- A first look at metabolic liabilities
Drug metabolism:
- CYP inhibition and substrate probabilities — these are inputs to a drug–drug interaction assessment, not a DDI assessment
- Hepatocyte and microsomal clearance estimates, for ranking rather than as values
- Planning which in vitro metabolism studies to run first
It does not predict metabolic pathways, metabolite structures, or drug–drug interactions.
Performance characteristics
Batch processing efficiency
Scalability:
- Support for thousands of compounds per job
- Parallel processing with automatic load balancing
- GPU acceleration for large prediction batches
- Memory optimization for high-throughput screening
Error handling:
- Individual compound failure handling
- Detailed error reporting per molecule
- Batch continuation despite individual failures
- Retry logic for transient service issues
Result management
Output formats:
- CSV exports: Tabular format for spreadsheet analysis
- JSON artifacts: Structured data for programmatic access
- Interactive dashboards: Real-time result visualization
- Statistical summaries: Distribution analysis across datasets
Result interpretation:
- Scoring systems: Standardized risk categories (Low/Medium/High)
- Confidence intervals: Prediction uncertainty quantification
- Comparative analysis: Side-by-side evaluation of compound series
- Trend identification: Property optimization patterns
Integration with .bloom* ecosystem
Upstream data sources
Chemistry tools:
- DeepPurpose: Evaluate generated molecule properties
- AiZynthFinder: Assess synthetic intermediates
- Fragment libraries: Screen building block collections
- Virtual screening: ADMET evaluation of docking hits
Downstream applications
Decision support:
- Multi-parameter optimization workflows
- Compound advancement criteria definition
- Risk-benefit analysis frameworks
- Portfolio prioritization strategies
Experimental planning:
- Guide in vitro assay selection
- Plan in vivo pharmacokinetic studies
- Design formulation development strategies
- Optimize preclinical candidate selection
Workflow automation
High-throughput pipelines:
- Automated batch processing workflows
- Integration with compound management systems
- Real-time result monitoring and alerting
- Quality control and data validation
Research collaboration:
- Shared prediction results across teams
- Integration with electronic lab notebooks
- Audit trails for regulatory compliance
- Reproducible analysis workflows
Chat Usage
Example Prompts
- "Run ADMET-AI on CC(=O)Oc1ccccc1C(=O)O" (aspirin)
- "Screen these 10 compounds through ADMET-AI and export results as CSV"
- "Predict drug-likeness for gefitinib and erlotinib — compare hERG profiles"
Workflow Chaining
- Feeds into: Compound Passport (ADMET section), comparison tables
- Accepts from: PubChem, ZINC, ChEMBL (compound SMILES), REINVENT/GenMol (generated molecules)
FAQ
Read next
Was this page helpful?